Cargando…

Stage III uterine serous carcinoma: modern trends in multimodality treatment

OBJECTIVE: To examine outcomes in a modern treatment era for stage III uterine serous carcinoma (USC). METHODS: Fifty women were retrospectively identified as 2009 International Federation of Gynecology and Obstetrics stage III USC patients who received radiotherapy (RT) at our institution between 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jessie Y., Young, Melissa R., Huang, Gloria, Litkouhi, Babak, Santin, Alessandro, Schwartz, Peter E., Damast, Shari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286763/ https://www.ncbi.nlm.nih.gov/pubmed/32266802 http://dx.doi.org/10.3802/jgo.2020.31.e53

Ejemplares similares

High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma
por: Damast, Shari, et al.
Publicado: (2015)

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Improved survival of patients with hypermutation in uterine serous carcinoma
por: Santin, Alessandro D., et al.
Publicado: (2015)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management
por: Lopez, Salvatore, et al.
Publicado: (2018)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
por: Han, Chanhee, et al.
Publicado: (2018)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
por: Santin, A D, et al.
Publicado: (2005)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
por: ElSahwi, Karim S., et al.
Publicado: (2011)

An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva
por: Li, Jessie Y., et al.
Publicado: (2021)

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
por: Santin, A D, et al.
Publicado: (2004)

Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer
por: Qian, Jack M., et al.
Publicado: (2017)

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review
por: Damast, Shari, et al.
Publicado: (2016)

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
por: Ferrari, Francesca, et al.
Publicado: (2015)

Central Serous Chorioretinopathy: Multimodal Imaging and Management Options
por: Iyer, Prashanth G., et al.
Publicado: (2020)

Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy
por: Tate, Keisei, et al.
Publicado: (2018)

The Impact of Adjuvant Management Strategies on Outcomes in Women With Early Stage Uterine Serous Carcinoma
por: Cook, Andrew, et al.
Publicado: (2021)

Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?
por: Lefebvre, Manon, et al.
Publicado: (2023)

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
por: Cocco, E, et al.
Publicado: (2009)

Management of Women with Surgically Staged 1 Uterine Papillary Serous Cancer
por: Elit, Laurie, et al.
Publicado: (2011)

Pathogenesis and Clinical Management of Uterine Serous Carcinoma
por: Zhang, Li, et al.
Publicado: (2020)

Abdominopelvic Metastasis of Endometrial Serous Carcinoma Initially Misdiagnosed as Early-Stage Low-Grade Endometrioid Carcinoma: The Importance of Recognizing Minimal Uterine Serous Carcinoma
por: Han, Jiheun, et al.
Publicado: (2020)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Comprehensive pelvic and paraaortic lymphadenectomy in patients with apparently early stage uterine serous carcinoma – an anachronism?
por: Emons, Günter
Publicado: (2020)

Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma
por: Casarin, Jvan, et al.
Publicado: (2020)

Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
por: Österberg, Lovisa, et al.
Publicado: (2009)

A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma
por: Shimizu, Maho, et al.
Publicado: (2021)

Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic
por: Damast, Shari, et al.
Publicado: (2022)

Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers
por: Bellone, Stefania, et al.
Publicado: (2023)

Acute Central Serous Chorioretinopathy Subtypes as Assessed by Multimodal Imaging
por: Arrigo, Alessandro, et al.
Publicado: (2021)

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
por: English, Diana P, et al.
Publicado: (2014)

Which is worse: uterine papillary serous carcinomas or carcinosarcomas?
por: Song, Taejong, et al.
Publicado: (2011)

Papillary Serous Carcinoma of the Uterine Cervix with Lung Metastasis
por: Khan, Maliha, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0dejlfo3dm1nvucfi7p1ds2m1p